Basic information Description References Safety Supplier Related
ChemicalBook >  Product Catalog >  API >  Circulatory system drugs >  Angina Pectoris Drugs >  Trimetazidine dihydrochloride

Trimetazidine dihydrochloride

Basic information Description References Safety Supplier Related

Trimetazidine dihydrochloride Basic information

Product Name:
Trimetazidine dihydrochloride
Synonyms:
  • 1-(2,3,4-TRIMETHOXYBENZYL)PIPERAZINE DIHYDROCHLORIDE
  • 1-[(2,3,4-Trimethoxy-phenyl)methyl]piperazine Dihydrochloride
  • Vastarel F
  • Yoshimilon
  • 1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride,Trimetazidine dihydrochloride
  • Trimetazidine 3HCl
  • Takkmint
  • Youmetazine
CAS:
13171-25-0
MF:
C14H24Cl2N2O3
MW:
339.26
EINECS:
236-117-0
Product Categories:
  • Building Blocks
  • C14 to C15
  • Intermediates & Fine Chemicals
  • Chemical Synthesis
  • Heterocyclic Building Blocks
  • Piperazines
  • Pharmaceuticals
  • 13171-25-0
  • API
Mol File:
13171-25-0.mol
More
Less

Trimetazidine dihydrochloride Chemical Properties

Melting point:
231-235 °C(lit.)
storage temp. 
Refrigerator
solubility 
Freely soluble in water, sparingly soluble in alcohol.
form 
Solid
color 
White to Off-White
Merck 
14,9705
Stability:
Hygroscopic
InChIKey
XIRALXKCBGTYSC-UHFFFAOYSA-N
CAS DataBase Reference
13171-25-0(CAS DataBase Reference)
More
Less

Safety Information

Hazard Codes 
Xn,Xi
Risk Statements 
22-36/37/38
Safety Statements 
26-36
WGK Germany 
3
RTECS 
TM2976100
HazardClass 
IRRITANT
HS Code 
29339900
Toxicity
LD50 in male, female mice, rats (mg/kg): 91, 107, 124, 124 i.v.; 264, 245, 327, 288 i.p.; 528, 608, 1147, 987 orally (Harpey)

MSDS

More
Less

Trimetazidine dihydrochloride Usage And Synthesis

Description

Trimetazidine dihydrochloride is the dihydrochloride salt of Trimetazidine. It is a drug used for the treatment of angina pectoris. It is capable of improving the left ventricular function in diabetic patients suffering coronary heart disease as well as treating the symptoms of patients suffering heart failure of different etiologies. It takes effects through acting as an anti- ischemic metabolic agent being capable of improving the utilization efficiency of myocardial glucose by inhibiting the metabolism of fatty acid (through inhibiting the activity of mitochondrial long- chain 3-ketoacyl coenzyme A Thiolase). The shift from fatty acid oxidation to glucose oxidation optimizes cellular energy process in cells exposed to hypoxia or ischaemia, further maintaining the intracellular ATP levels and ensuring the normal function of ionic pumps and transmembrane sodium-potassium flow to maintain cellular homeostasis.

References

Fragasso, G, et al. "A randomized clinical trial of trimetazidine, a partial free fatty acid oxidation inhibitor, in patients with heart failure. " Journal of the American College of Cardiology 48.5 (2006):992.
Tuunanen, H, et al. "Trimetazidine, a metabolic modulator, has cardiac and extracardiac benefits in idiopathic dilated cardiomyopathy."Circulation 118.12(2008):1250.
Kantor, P. F., et al. "The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase."Circulation Research 86.5(2000):580.
Stanley, W. C., and M. Marzilli. "Metabolic therapy in the treatment of ischaemic heart disease: the pharmacology of trimetazidine. "Fundamental & Clinical Pharmacology 17.2(2003):133–145.
Kantor, Paul F., et al. "The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase." Circulation research 86.5 (2000): 580-588.

Description

Trimetazidine (hydrochloride) (Item No. 18165) is an analytical reference standard that is structurally categorized as a piperazine. It decreases fatty acid β-oxidation by reversibly inhibiting mitochondrial long-chain 3-ketoacyl thiolase (IC50 = 75 nM). This, in turn, stimulates glucose oxidation. In ischemic heart, trimetazidine reduces ischemia/reperfusion injury in clinical trials. Compounds that reduce mitochondrial fatty acid β-oxidation, including trimetazidine, have shown clinical efficacy against chronic stable angina in clinical trials. In part because of its ability to ameliorate testosterone cardiotoxicity, trimetazidine has been classified as a prohibited substance by the World Anti-Doping Agency. This product is intended for research and forensic applications.

Chemical Properties

Crystalline Solid

Uses

Antianoxic

Uses

1-(2,3,4-Trimethoxybenzyl)piperazine dihydrochloride or trimetazidine dihydrochloride can be used as a building block to synthesize:

  • Phenylpropyl trimetazidine derivatives with potent cerebral vasodilator activity.
  • Benzoylguanidine-trimetazidine derivatives for myocardial ischemic-reperfusion activity studies.

Uses

Coronary vasodilator. Antianginal

Definition

ChEBI: Trimetazidine hydrochloride is an aromatic amine.

Trimetazidine dihydrochloride Supplier

Beijing Jialin Pharmaceutical Co., Ltd. Gold
Tel
010-85392752
J & K SCIENTIFIC LTD.
Tel
010-82848833 400-666-7788
Email
jkinfo@jkchemical.com
Meryer (Shanghai) Chemical Technology Co., Ltd.
Tel
021-61259108 18621169109
Email
market03@meryer.com
Alfa Aesar
Tel
400-6106006
Email
saleschina@alfa-asia.com
TAIYUAN RHF CO.,LTD.
Tel
+86 351 7031519
Email
sales@RHFChem.com